Mohammad Alyamani

About

Dr. Mohammad Alyamani is an accomplished Research Assistant Professor with a strong focus on metabolic changes in prostate cancer. With nearly two decades of experience, Dr. Alyamani has been instrumental in developing and optimizing LC-MS methodologies for small molecule analysis, establishing a reputation as a leading expert in the field.
Throughout a distinguished career, Dr. Alyamani has published 19 peer-reviewed research articles, including five as first author, with an impressive overall h-index of 16. A recognized interdisciplinary collaborator, Dr. Alyamani has successfully led impactful research projects, securing competitive funding such as a CDMRP Prostate Cancer Research Program grant.
Dr. Alyamani has received 14 prestigious awards, further solidifying expertise in mass spectrometry, bioanalytical chemistry, and project management. A dedicated mentor and leader, Dr. Alyamani has supervised postdoctoral fellows and technicians, spearheading research on steroid metabolism, cancer progression, and biomarker discovery.
Currently serving as an Assistant Professor of Research at the University of Miami's Miller School of Medicine, Dr. Alyamani continues to pioneer groundbreaking work in prostate cancer research, leveraging advanced metabolomics methodologies to translate scientific findings into clinically relevant applications.
Passionate about driving innovation in oncology and metabolomics, Dr. Alyamani welcomes collaborations that foster interdisciplinary research and advance precision medicine approaches.

Employment

• University of Miami Health System Research Assistant Professor
  2023 - Present
• Cleveland Clinic Lerner Research Institute Research Associate
  2020 - Present
• Cleveland Clinic Lerner Research Institute Postdoctoral Research Fellow
  2017 - 2020
• Cleveland Clinic Lerner Research Institute PhD Research Assistant
  2014 - 2017

Education

• Cleveland State University PhD
  2014 - 2017

Projects & Funding

Projects & funding information is unavailable.

Publications (20)

• 3β-HSD1–Mediated Steroid Back-Conversion Maintains Androgen Signaling in Prostate Cancer
  Molecular Cancer Research 2026 DOI: 10.1158/1541-7786.MCR-26-0243
  +Save
• Approaches to assessing 3β-hydroxysteroid dehydrogenase-1
  Methods in Enzymology 2023 DOI: 10.1016/bs.mie.2023.04.002
  +Save
• BMX controls 3βHSD1 and sex steroid biosynthesis in cancer
  Journal of Clinical Investigation 2023 DOI: 10.1172/JCI163498
  +Save
• Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation
  Journal of Clinical Investigation 2023 DOI: 10.1172/JCI161913
  +Save
• Elevated periprostatic venous testosterone correlates with prostate cancer progression after radical prostatectomy
  Journal of Clinical Investigation 2023 DOI: 10.1172/JCI171117
  +Save
• Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation
  Science Translational Medicine 2021 DOI: 10.1126/scitranslmed.abe8226
  +Save
• HSD3B1 genotype identifies glucocorticoid responsiveness in severe asthma
  Proceedings of the National Academy of Sciences 2020 DOI: 10.1073/pnas.1918819117
  +Save
• Abiraterone acetate treatment lowers 11-oxygenated androgens
  European Journal of Endocrinology 2020 DOI: 10.1530/EJE-19-0905
  +Save
• Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure
  Annals of Oncology 2020 DOI: 10.1016/j.annonc.2019.12.002
  +Save
• Rapid and structure-specific cellular uptake of selected steroids
  PLOS ONE 2019 DOI: 10.1371/journal.pone.0224081
  +Save